vs
Hour Loop, Inc（HOUR）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Hour Loop, Inc的季度营收约是REGENXBIO Inc.的1.8倍（$56.1M vs $30.3M），Hour Loop, Inc净利率更高（-1.2% vs -221.3%，领先220.2%），REGENXBIO Inc.同比增速更快（43.0% vs 3.0%），Hour Loop, Inc自由现金流更多（$3.0M vs $-52.8M），过去两年Hour Loop, Inc的营收复合增速更高（50.7% vs 39.4%）
Hour Loop Inc.是一家电商零售企业，主营家居用品、服饰、玩具、电子配件及日常消费必需品，主要依托第三方主流线上平台开展业务，核心客群集中在北美地区，专注为大众消费者提供高性价比的日常商品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
HOUR vs RGNX — 直观对比
营收规模更大
HOUR
是对方的1.8倍
$30.3M
营收增速更快
RGNX
高出40.0%
3.0%
净利率更高
HOUR
高出220.2%
-221.3%
自由现金流更多
HOUR
多$55.8M
$-52.8M
两年增速更快
HOUR
近两年复合增速
39.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $56.1M | $30.3M |
| 净利润 | $-657.3K | $-67.1M |
| 毛利率 | 49.6% | — |
| 营业利润率 | -1.5% | -190.0% |
| 净利率 | -1.2% | -221.3% |
| 营收同比 | 3.0% | 43.0% |
| 净利润同比 | 57.0% | -31.2% |
| 每股收益（稀释后） | $-0.02 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOURRGNX
| Q4 25 | $56.1M | $30.3M | ||
| Q3 25 | $33.4M | $29.7M | ||
| Q2 25 | $27.1M | $21.4M | ||
| Q1 25 | $25.8M | $89.0M | ||
| Q4 24 | $54.4M | $21.2M | ||
| Q3 24 | $31.1M | $24.2M | ||
| Q2 24 | $28.1M | $22.3M | ||
| Q1 24 | $24.7M | $15.6M |
净利润HOURRGNX
| Q4 25 | $-657.3K | $-67.1M | ||
| Q3 25 | $530.6K | $-61.9M | ||
| Q2 25 | $1.2M | $-70.9M | ||
| Q1 25 | $654.5K | $6.1M | ||
| Q4 24 | $-1.5M | $-51.2M | ||
| Q3 24 | $469.6K | $-59.6M | ||
| Q2 24 | $649.1K | $-53.0M | ||
| Q1 24 | $1.1M | $-63.3M |
毛利率HOURRGNX
| Q4 25 | 49.6% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 57.2% | — | ||
| Q1 25 | 54.7% | — | ||
| Q4 24 | 45.7% | 70.2% | ||
| Q3 24 | 54.8% | 48.8% | ||
| Q2 24 | 55.7% | 52.5% | ||
| Q1 24 | 58.6% | 72.6% |
营业利润率HOURRGNX
| Q4 25 | -1.5% | -190.0% | ||
| Q3 25 | 2.2% | -176.3% | ||
| Q2 25 | 6.0% | -296.3% | ||
| Q1 25 | 3.6% | 13.6% | ||
| Q4 24 | -4.5% | -242.1% | ||
| Q3 24 | 2.3% | -256.6% | ||
| Q2 24 | 3.3% | -251.3% | ||
| Q1 24 | 6.2% | -408.8% |
净利率HOURRGNX
| Q4 25 | -1.2% | -221.3% | ||
| Q3 25 | 1.6% | -208.3% | ||
| Q2 25 | 4.3% | -331.8% | ||
| Q1 25 | 2.5% | 6.8% | ||
| Q4 24 | -2.8% | -241.3% | ||
| Q3 24 | 1.5% | -246.3% | ||
| Q2 24 | 2.3% | -237.7% | ||
| Q1 24 | 4.3% | -405.4% |
每股收益（稀释后）HOURRGNX
| Q4 25 | $-0.02 | $-1.30 | ||
| Q3 25 | $0.01 | $-1.20 | ||
| Q2 25 | $0.04 | $-1.38 | ||
| Q1 25 | $0.02 | $0.12 | ||
| Q4 24 | $-0.04 | $-0.99 | ||
| Q3 24 | $0.01 | $-1.17 | ||
| Q2 24 | $0.02 | $-1.05 | ||
| Q1 24 | $0.03 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $102.7M |
| 总资产 | $23.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HOURRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | $2.9M | $338.7M |
股东权益HOURRGNX
| Q4 25 | $7.0M | $102.7M | ||
| Q3 25 | $7.7M | $161.5M | ||
| Q2 25 | $7.2M | $213.7M | ||
| Q1 25 | $5.8M | $274.2M | ||
| Q4 24 | $5.2M | $259.7M | ||
| Q3 24 | $6.7M | $301.4M | ||
| Q2 24 | $6.2M | $348.3M | ||
| Q1 24 | $5.5M | $390.7M |
总资产HOURRGNX
| Q4 25 | $23.8M | $453.0M | ||
| Q3 25 | $31.6M | $525.2M | ||
| Q2 25 | $23.0M | $581.0M | ||
| Q1 25 | $19.1M | $490.9M | ||
| Q4 24 | $20.0M | $466.0M | ||
| Q3 24 | $32.4M | $519.1M | ||
| Q2 24 | $20.2M | $569.4M | ||
| Q1 24 | $16.7M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $3.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 5.3% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.5M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流HOURRGNX
| Q4 25 | $3.0M | $-52.3M | ||
| Q3 25 | $500.4K | $-56.0M | ||
| Q2 25 | $-901.5K | $-49.3M | ||
| Q1 25 | $-23.9K | $33.6M | ||
| Q4 24 | $1.5M | $-31.6M | ||
| Q3 24 | $-2.2M | $-40.5M | ||
| Q2 24 | $456.2K | $-45.5M | ||
| Q1 24 | $492.9K | $-55.5M |
自由现金流HOURRGNX
| Q4 25 | $3.0M | $-52.8M | ||
| Q3 25 | $449.3K | $-56.5M | ||
| Q2 25 | $-901.6K | $-49.7M | ||
| Q1 25 | $-24.6K | $32.6M | ||
| Q4 24 | $1.5M | $-32.7M | ||
| Q3 24 | $-2.2M | $-40.9M | ||
| Q2 24 | $439.4K | $-46.0M | ||
| Q1 24 | $475.1K | $-56.0M |
自由现金流率HOURRGNX
| Q4 25 | 5.3% | -174.0% | ||
| Q3 25 | 1.3% | -189.9% | ||
| Q2 25 | -3.3% | -232.8% | ||
| Q1 25 | -0.1% | 36.6% | ||
| Q4 24 | 2.8% | -154.2% | ||
| Q3 24 | -7.0% | -168.9% | ||
| Q2 24 | 1.6% | -206.2% | ||
| Q1 24 | 1.9% | -358.5% |
资本支出强度HOURRGNX
| Q4 25 | 0.0% | 1.7% | ||
| Q3 25 | 0.2% | 1.7% | ||
| Q2 25 | 0.0% | 1.8% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率HOURRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.94× | — | ||
| Q2 25 | -0.77× | — | ||
| Q1 25 | -0.04× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | -4.64× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.46× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOUR
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
